DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT

• 收藏
• 分享

专利权人:

SRI INTERNATIONAL

发明人:

Thomas R. Webb,Jaehyeon Park,Chandraiah Lagisetti

申请号：

US16334229

公开号：

US20190255059A1

申请日:

2017.09.29

申请国别(地区):

US

年份:

2019

代理人:

摘要：

This disclosure generally relates to dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/